• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

GE9:GR

28.340 EUR 0.350 1.25%

As of 13:47:44 ET on 07/11/2014.

Snapshot for Genmab A/S (GE9)

Open: 27.965 Day's Range: 27.400 - 28.920 Volume: 22
Previous Close: 27.990 52wk Range: 21.000 - 34.615 1-Yr Rtn: +19.53%

Stock Chart for GE9

No chart data available.
  • GE9:GR 28.340
  • 1D
  • 1M
  • 1Y
27.990
Interactive GE9 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GE9

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) 64.1816
Relative P/E vs. DAX -
Earnings Per Share (DKK) (ttm) -
Est. EPS (DKK) (12/2014) 3.2920
Est. PEG Ratio -
Market Cap (M EUR) 1,606.52
Shares Outstanding (M) 56.69
30 Day Average Volume 344
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/13/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GE9

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GE9

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GE9

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil